Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Effects of pravastatin (CS-514) on biliary lipid metabolism in patients with hyperlipidemia.

Horiuchi I, Ohya T, Tazuma S, Mizuno T, Takizawa I, Kajiyama G.

Metabolism. 1991 Mar;40(3):226-30.

PMID:
1900342
2.

Effect of pravastatin on biliary lipid composition and bile acid synthesis in familial hypercholesterolaemia.

Hoogerbrugge-vd Linden N, de Rooy FW, Jansen H, van Blankenstein M.

Gut. 1990 Mar;31(3):348-50.

3.

Acute effects of HMG-CoA reductase inhibitors on biliary lipids in patients with interrupted enterohepatic circulation.

Muraca M, Baggio G, Miconi L, Vilei MT, Martini S, Gabelli C, Belluco C, Lise M, Crepaldi G.

Eur J Clin Invest. 1991 Apr;21(2):204-8.

PMID:
1905632
4.

Effects of long-term treatment with low-dose pravastatin on biliary lipid and bile acid composition in patients with nonfamilial hyperlipoproteinemia.

Tazuma S, Takizawa I, Kunita T, Mizuno T, Watanabe T, Teramen K, Horikawa K, Ochi H, Yamashita Y, Aihara N, et al.

Metabolism. 1995 Nov;44(11):1410-2.

PMID:
7476326
5.
6.

Effects of cerivastatin sodium, a new HMG-CoA reductase inhibitor, on biliary lipid metabolism in patients with hypercholesterolemia.

Tazuma S, Yamashita G, Ochi H, Miura H, Kajihara T, Hattori Y, Miyake H, Nishioka T, Hyogo H, Sunami Y, Yasumiba S, Kajiyama G.

Clin Ther. 1998 May-Jun;20(3):477-85.

PMID:
9663363
8.

Effect of CS-514, a competitive inhibitor of hydroxymethylglutaryl coenzyme A reductase, on cholesterol gallstone formation in hamsters.

Koide K, Hayashi K, Horiuchi I, Kajiyama G.

Biochim Biophys Acta. 1989 Sep 11;1005(1):65-71.

PMID:
2505850
9.

Effects of pravastatin and ursodeoxycholic acid on cholesterol and bile acid metabolism in patients with cholesterol gallstones.

Okamoto S, Nakano K, Kosahara K, Kishinaka M, Oda H, Ichimiya H, Chijiiwa K, Kuroki S.

J Gastroenterol. 1994 Feb;29(1):47-55.

PMID:
8199696
10.

Changes in biliary lipid output after interruption of pravastatin treatment in humans.

Hillebrant CG, Eriksson M, Nyberg B, Einarsson K.

Eur J Clin Invest. 1996 Dec;26(12):1160-5.

PMID:
9013093
11.

Effect of gemfibrozil administration on biliary lipid secretion in hyperlipidemic patients. A crossover study with clofibrate.

Mazzella G, Bazzoli F, Villanova N, Simoni P, Festi D, Roda A, Aldini R, Roda E.

Scand J Gastroenterol. 1990 Dec;25(12):1227-34.

PMID:
2274744
12.

Effect of chenodeoxycholic acid on serum and biliary lipids in patients with hyperlipoproteinaemia.

Angelin B, Einarsson K, Leijd B.

Clin Sci Mol Med. 1978 Apr;54(4):451-5.

PMID:
639478
14.

Pharmacokinetics and pharmacodynamics of pravastatin alone and with cholestyramine in hypercholesterolemia.

Pan HY, DeVault AR, Swites BJ, Whigan D, Ivashkiv E, Willard DA, Brescia D.

Clin Pharmacol Ther. 1990 Aug;48(2):201-7.

PMID:
2116260
16.

Managing dyslipidemia in the high-risk patient.

Stein EA.

Am J Cardiol. 2002 Mar 7;89(5A):50C-57C. Review.

PMID:
11900720
17.

Effect of pravastatin and atorvastatin on glucose metabolism in nondiabetic patients with hypercholesterolemia.

Ishikawa M, Namiki A, Kubota T, Yajima S, Fukazawa M, Moroi M, Sugi K.

Intern Med. 2006;45(2):51-5. Epub 2006 Feb 15.

18.
19.

Clinical efficacy of pravastatin for hyperlipidemia in patients with type 2 diabetes mellitus.

Tawata M, Miwa I, Tsuchiya K, Ozawa M, Shindo H, Wakasugi M, Onaya T.

Arzneimittelforschung. 1995 Jun;45(6):704-8.

PMID:
7646575
20.

Effects of combined treatment with pravastatin and ursodeoxycholic acid on hepatic cholesterol metabolism.

Hillebrant CG, Nyberg B, Gustafsson U, Sahlin S, Björkhem I, Rudling M, Einarsson C.

Eur J Clin Invest. 2002 Jul;32(7):528-34.

PMID:
12153554
Items per page

Supplemental Content

Write to the Help Desk